ESI-MS (m/z, Figure S6) The 1 H NMR and 13 C NMR of compound 9 were identical to end-product 11(DMSO, Figure   S19 ).
ESI-MS (m/z, Figure S9 
Monitoring enantiomeric purity of BCN amino acid
Derivatization of an amino acid with FDAA produced a diastereomer referred to as DNPAamino acid. L-BCN amino acid (1.9 mg, 7.8 M) was placed in a 2 ml plastic tube. The tube was added with 300 l acetone solution of FDAA (3 mg, 11 M), the molar ratio of FDAA to amino acid 1.4: 1, followed by NaHCO 3 (1 M, 60 l, 60 M). The contents were mixed at 30 -40 °C for one hour with frequent mixing. After cooling down to rt, HCl (2 M, 30 l, 60 M) was added to the reaction mixture. The DNPA-amino acid can be separated and estimated by HPLC with the linear gradient of MeCN from 5% to 95% within 20 min at a flow rate of 1 ml/min and the UV detection at 340 nm. The absorption spectra in RP-HPLC showed four peaks, and the four peaks were measured combined with mass spectrometry to confirm the purity. The results showed that the product was only found in peak 4, while no product in peak 3. It has been recognized that the peak 4 was the FDAA derivative of L-BCN amino acid. Moreover, acetone solution of FDAA was injected for HPLC as well, and the results showed that the FDAA had the same absorption spectra and retention behavior as that with peak 3. It is evident that the tetrazine-containing amino acid was L-isomer and can be used for peptide synthesis. 
Synthesis of tetrazine-containing amino acid 13 and 14
S-9 Figure S21) All kinetic experiments were conducted under pseudo first order conditions. The pseudo first order rate constants were obtained by plotting the natural log of the concentration of the limiting reactant versus time in seconds. The second order rate constants and half-lives were extrapolated from the rate measurements derived under pseudo first order conditions.
Kinetic experiments of the reaction between BCN and tetrazine derivatives
As illustrated in Scheme 1, an equal volume of the Phosphate Buffered solution (PBS) of 11
(2  10 -4 M) and the PBS of 13 (2  10 -5 M) was mixed into the cuvette at room temperature . The absorption spectrum of the starting material 13 under the absorption peak at 523 nm, because the product 16 and its isomers had no absorption at 523 nm, the absorbance value was recorded once every 1 seconds. An exponential curve was used for calculating the reaction rate, the calculated pseudo first order reaction constant kobs = 0.13  0.01, the half-life t 1/2 = 5.4 s, and further calculations obtained second-order reaction rate constant k 2 = 513  10 M -1 S -1 (see Figure S3 ).
As illustrated in Scheme 1, an equal volume of the phosphate buffered solution (PBS) of 11 (4  10 -3 M) and the PBS of 14 (4  10 -4 M) was mixed into the cuvette at rt. The absorption spectrum of the starting material 14 under the absorption peak at 527 nm, compound 14 reacted with compound 11 by an identical procedure as described for compound 13. The changes in the absorbance spectrum in 527 nM of the reaction were observed, the absorbance value was recorded once every 5 seconds. An exponential curve was used for calculating the reaction rate, the calculated pseudo first order reaction constant kobs = 5.78 × 10 -3  6 × 10 -6 , the half-life t 1/2 = 120 s, and further calculations obtained second-order reaction rate constant k 2 = 1.45  0.05 M -1 S -1 (see Figure S4 ). Cancer cell labeling. to afford the fluorophore and tetrazine modified cetuximab. 4 To confirm the biological utility of the new BCN and tetrazine derivatives, 13 was chosen as the representative compound for validation in pretargeted labeling studies with live A431 epidermoid carcinoma cells. Since we have already demonstrated that tetrazine 13 possessed faster reaction kinetic, better serum stability, higher water solubility, and easier synthesis/purification, so we attempted to demonstrate that the tetrazine from this study was still a practical cycloaddition partner with BCN for bioorthogonal use. A431 epidermoid carcinoma cells, which overexpressed HER2/neu receptors, have been shown to be useful in pretargeted cell labeling assays with a BCNtetrazine system.
To confirm the cycloaddition reactivity in a biological environment, A431 cells and modified antibody were incubated at 37 °C for 3 h and washed to clean the unbounded antibody of the cell surface. L-BCN-Cy5.5 conjugate reacted with the antibody, which was modified with fluorophore or tetrazine, in 10% fetal bovine serum and Hanks' balanced salt solution at 37 °C for 1 hour via IED-DA reaction (Figure 1 ). Then a washing step was needed to remove the unreacted L-BCN-S-13
Cy5.5 conjugate. The unlabeled cetuximab and L-BCN-Cy5.5 conjugate or fluorophore and tetrazine modified cetuximab and unlabeled Cy5.5 were taken as the control experiments. In the end, the cellular changes were monitored by the fluorescence microscopy in rhodamine channel and near infrared channel (NIR) respectively. The results suggested that the antibody could be visualized clearly in rhodamine channel, and the covalently bound L-BCN-Cy5.5 conjugate could be monitored apparently in NIR channel, while control experiments showed no NIR fluorescence ( Figure 2 ). This study further demonstrated that our selected BCN and tetrazine derivatives are useful in bioorthogonal labeling on par with the previously reported compounds. Figure S1 . Derivatization of the BCN amino acid with FDAA produced a diastereomer referred to as DNPA-amino acid. The DNPA-amino acid can be separated and estimated by HPLC, and the results showed four peaks of absorption spectra in RP-HPLC. Figure S2 . The stability of 14 in 20% piperidine/DMF at 20.0 ± 0.1 °C monitored at 527 nm. A 4.1% decrease in absorption was observed within 2 h. Figure S3 . Kinetics of the reaction of 11 (2  10 -4 M) with 13 (2  10 -5 M) in deionized water, monitored by UV-vis at 523 nm. Kinetic runs were performed in triplicate (all data was presented above) and fitted to an observed first-order rate constant (k obs ), which was used to calculate the second order rate constant. Figure S4 . Kinetics of the reaction of 11 (4  10 -3 M) with 14 (4  10 -4 M) in
